红日药业(300026.SZ)：注射用胸腺法新通过仿制药一致性评价

Core Viewpoint - Hongri Pharmaceutical (300026.SZ) has received approval from the National Medical Products Administration for the supplementary application of Thymosin Injection, a synthetic peptide immunomodulator composed of 28 amino acids [1] Group 1: Product Information - The drug Thymosin Injection is indicated for chronic hepatitis B and as an enhancer of vaccine immune response in immunocompromised patients [1] - It is particularly beneficial for patients with suppressed immune systems, including those undergoing chronic hemodialysis and elderly patients, enhancing their immune response to viral vaccines such as influenza and hepatitis B vaccines [1]